



(11) EP 1 332 759 A1

(19)  **Europäisches Patentamt**  
European Patent Office  
Office européen des brevets

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
06.08.2003 Bulletin 2003/32

(51) Int Cl.7: **A61K 31/7016**, A61K 31/702,  
A61K 31/7012, A23L 1/09,  
A23L 1/30

(21) Application number: 03002166.1

(22) Date of filing: 03.02.2003

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR**  
**HU IE IT LI LU MC NL PT SE SI SK TR**  
Designated Extension States:  
**AL LT LV MK RO**

- Kamiya, Toshikazu,  
Tsukuba Research Laboratories  
Tsukuba-shi, Ibaraki 305-0841 (JP)
- Endo, Tetsuo  
Stanford, CA 94305-6090 (US)
- Koizumi, Satoshi, Head Office  
Chiyoda-ku, Tokyo 100-8185 (JP)

(30) Priority: 04.02.2002 JP 2002027089

(71) Applicant: **KYOWA HAKKO KOGYO CO., LTD.**  
Chiyoda-ku, Tokyo 100-8185 (JP)

(74) Representative: **VOSSIUS & PARTNER**  
Siebertstrasse 4  
81675 München (DE)

(72) Inventors:  
• Takada, Miho, Tsukuba Research Laboratories  
Tsukuba-shi, Ibaraki 305-0841 (JP)

(54) **Pharmaceutical and nutritional compositions containing a di- or oligosaccharide as insulin secretion promoter**

(57) Provided are an insulin secretion promoter, an agent for suppressing the elevation of a blood glucose level, an agent for ameliorating diabetes mellitus, an agent for promoting growth of an animal, and an agent for increasing an insulin level in breast milk. These promoter and agents comprise at least one member select-

ed from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

EP 1 332 759 A1

**Description**Technical Field

5 [0001] The present invention relates to an insulin secretion promoter, an agent for suppressing the elevation of a blood glucose level and an agent for ameliorating diabetes mellitus, an agent for promoting growth of an animal, and an agent for increasing an insulin level in breast milk. Additionally, the present invention relates to a food or drink, a feed, or an additive for foods, drinks or feeds, which has an activity to increase insulin secretion, to suppress the elevation of a blood glucose level, to ameliorate diabetes mellitus, or to increase an insulin level in breast milk. Further, the present invention relates to a nutritious composition, a feed, and an additive for nutritious compositions or for feeds, which has an activity to promote growth of an animal.

10 [0002] Moreover, the present invention relates to a pharmaceutical composition comprising the insulin secretion promoter or the agents of the present invention.

15 Background of the Invention

[0003] It has been known that diabetes mellitus is a risk factor of brain stroke and cardiac diseases. Additionally, diabetes mellitus also causes complications such as retinopathy, neuropathy, renal disorders and cataract. A survey executed by the Ministry of Health and Welfare, Japan reported in 1998 showed that 6.9 million individuals are strongly suspected of having diabetes mellitus, and that the total number of individuals with the possibility of having diabetes mellitus is estimated to be 13.7 million.

20 [0004] The survey of Japan Hospital Association reveals that 12.4 % of persons in the hospital for a medical checkup in 1999 had abnormal glucose tolerance. The etiology of diabetes mellitus has not yet been elucidated completely. Diabetes mellitus is broadly classified as Type I diabetes mellitus with impairment of insulin secretion due to the damage of pancreatic beta-cells and Type II diabetes mellitus with reduced tissue sensitivity to insulin.

25 [0005] It has been said that Type II diabetes mellitus in the Japanese frequently involves relative shortage of insulin secretion. Therefore, agents for promoting insulin secretion have been used commonly.

30 [0006] It is thought that for preventing the onset of diabetes mellitus, reducing excess intake of animal fat, sugars and salt as well as increasing the intake of dietary fiber is effective. However, no regimen demonstrating a reliable effect has been established yet. As a method for therapeutically treating diabetes mellitus, insulin injection is accepted for Type I diabetes mellitus, while thiazolidine derivatives and biguanide as insulin resistance-ameliorating agents are used for Type II diabetes mellitus. Accepted foods for preventing or ameliorating diabetes mellitus include maltitol (a slightly digestible sugar), chitin and chitosan (dietary fiber), Gymnema sylvestre (a plant of the family Asclepiadaceae), and mulberry leaf (see Food Style 21, 2, No. 5, 1998). As the mechanism under which such food prevent and ameliorate diabetes mellitus, it is suggested that some sweet substances are hardly absorbed from intestinal tract and so, increase of blood glucose level is reduced by inhibiting saccharide degrading enzymes.

35 [0007] Furthermore, known agents or foods for ameliorating high blood glucose level on the basis of the inhibition of  $\alpha$ -glycosidase include monosaccharides such as L-arabinose, L-fucose, 2-deoxy-D-galactose, D-xylose, L-xylose, D-ribose, D-tagatose, D-ribulose, D-lyxose, and D-xylulose (USP 5,468,734).

40 [0008] It is known that insulin is a hormone secreted from the beta cells of pancreas and has activities to promote protein synthesis and glycogen synthesis in muscle and liver, to promote uptake and utilization of sugar in fat tissues, and to suppress lipolysis. It is also known that insulin promotes the growth of an infant. Furthermore, it is reported that the insulin level in breast milk increases as plasma insulin level increases due to post-meal or glucose loading (God. Zb. Med. Fak. Skopje., 21, 35-41. 1975).

45 [0009] It has been desired to develop a pharmaceutical agent, as well as a food or drink or an animal feed, which can effectively ameliorate, prevent or therapeutically treat diabetes mellitus via daily intake.

Disclosure of the Invention

50 [0010] It is an object of the present invention to provide an insulin secretion promoter, an agent for suppressing the elevation of a blood glucose level, an agent for ameliorating diabetes mellitus, an agent for promoting growth of an animal or an agent for increasing an insulin level in breast milk. Additionally, it is an object of the present invention to provide a food or drink, a feed, an additive for foods, drinks or feeds, which has an activity to promote insulin secretion, to suppress the elevation of a blood glucose level, to ameliorate diabetes mellitus, or to increase an insulin level in breast milk, as well as a nutritious composition, a feed, an additive for nutritious compositions, or for feeds, which has an activity to promote growth of an animal.

55 [0011] In accordance with the present invention the term "promoter" comprises an agent which promotes insulin secretion.

[0012] The present invention relates to the following aspects (1) to (69).

(1) An insulin secretion promoter, comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

(2) The insulin secretion promoter according to (1), where the di- or higher saccharide containing galactose is a di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.

(3) The insulin secretion promoter according to (2), where the di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di- or higher saccharide containing N-acetyllactosamine or lactose.

(4) The insulin secretion promoter according to (3), where the di- or higher saccharide containing N-acetyllactosamine is N-acetyllactosamine or lacto-N-neotetraose.

(5) The insulin secretion promoter according to (3), where the di- or higher saccharide containing lactose is lacto-N-neotetraose, globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.

(6) The insulin secretion promoter according to (1), where the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.

(7) A food or drink with an activity to promote insulin secretion, comprising the insulin secretion promoter according to any of (1) to (6).

(8) The food or drink according to (7), where the food or drink is a nutritious composition.

(9) A feed with an activity to promote insulin secretion, comprising the insulin secretion promoter according to any of (1) to (6).

(10) An additive for foods or drinks, which has an activity to promote insulin secretion, comprising the insulin secretion promoter according to any of (1) to (6).

(11) The additive for foods or drinks as according to (10), where the additive for foods or drinks is an additive for nutritious compositions for infants.

(12) An additive for feeds, which has an activity to promote insulin secretion, comprising the insulin secretion promoter according to any of (1) to (6).

(13) A method for promoting insulin secretion in animals, comprising administering the insulin secretion promoter according to any of (1) to (6) or feeding the feed according to (9) to animals.

(14) The method according to (13), where the animals are domestic mammals, domestic fowls, or cultivated fish.

(15) The agent according to any of (1) to (6), where the insulin secretion promoter is administered orally or by injections.

(16) An agent for suppressing the elevation of a blood glucose level comprising at least one member selected from the group consisting of a di-or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

(17) The agent according to (16), where the di-or higher saccharide containing galactose is a di-or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.

(18) The agent according to (17), where the di-or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di-or higher saccharide containing N-acetyllactosamine or lactose.

(19) The agent according to (18), where the di-or higher saccharide containing N-acetyllactosamine is N-acetyllactosamine or lacto-N-neotetraose.

(20) The agent according to (18), where the di-or higher saccharide containing lactose is lacto-N-neotetraose, globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.

(21) The agent according to (16), where the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.

(22) A food or drink with an activity to suppress the elevation of a blood glucose level, comprising the agent according to any of (16) to (21).

(23) A feed with an activity to suppress the elevation of a blood glucose level, comprising the agent according to any of (16) to (21).

(24) An additive for foods or drinks, which has an activity to suppress the elevation of a blood glucose level, comprising the agent according to any of (16) to (21).

(25) An additive for feeds, which has an activity to suppress the elevation of a blood glucose level, comprising the agent according to any of (16) to (21).

(26) A method for suppressing the elevation of a blood glucose level in animals, comprising administering the agent according to any of (16) to (21) to animals or feeding the feed according to (23) to animals.

(27) The method according to (26), where the animals are domestic mammals, domestic fowls, or cultivated fish.

(28) The agent according to any of (16) to (21), where the agent is administered orally or by injections.

(29) An agent for ameliorating diabetes mellitus comprising at least one member selected from the group consisting

of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

(30) The agent according to (29), where the di- or higher saccharide containing galactose is a di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.

(31) The agent according to (30), where the di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di- or higher saccharide containing N-acetylglucosamine or lactose.

(32) The agent according to (31), where the di- or higher saccharide containing N-acetylglucosamine is N-acetylglucosamine or lacto-N-neotetraose.

(33) The agent according to (31), where the di- or higher saccharide containing lactose is lacto-N-neotetraose, globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.

(34) The agent according to (29), where the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.

(35) A food or drink with an activity to ameliorate diabetes mellitus, comprising the agent according to any of (29) to (34).

(36) A feed with an activity to ameliorate diabetes mellitus, comprising the agent according to any of (29) to (34).

(37) An additive for foods or drinks, which has an activity to ameliorate diabetes mellitus, comprising the agent according to any of (29) to (34).

(38) An additive for feeds, which has an activity to ameliorate diabetes mellitus, comprising the agent according to any of (29) to (34).

(39) A method for ameliorating diabetes mellitus in animals, comprising administering the agent for ameliorating diabetes mellitus according to any of (29) to (34) to animals or feeding the feed according to (36) to animals.

(40) A method according to (39), where the animals are domestic mammals, domestic fowls or cultivated fish.

(41) The agent according to any of (29) to (34), where the agent is administered orally or by injections.

(42) An agent for promoting growth of an animal comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

(43) The agent according to (42), where the di- or higher saccharide containing galactose is a di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.

(44) The agent according to (43), where the di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di- or higher saccharide containing N-acetylglucosamine or lactose.

(45) The agent according to (44), where the di- or higher saccharide containing N-acetylglucosamine is N-acetylglucosamine or lacto-N-neotetraose.

(46) The agent according to (44), where the di- or higher saccharide containing lactose is lacto-N-neotetraose, globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.

(47) The agent according to (42), where the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.

(48) A nutritious composition for infants with an activity to promote growth of an infant, comprising the agent according to any of (42) to (47).

(49) A feed with an activity to promote growth of an animal infant, comprising the agent according to any of (42) to (47).

(50) An additive for nutritious compositions for infants, which has an activity to promote growth of an infant, comprising the agent according to any of (42) to (47).

(51) An additive for feeds, which has an activity to promote growth of an animal infant, comprising the agent according to any of (42) to (47).

(52) A method for promoting the growth of an animal, comprising administering the agent according to any of (42) to (47) to an animal or feeding a feed according to (49) to an animal.

(53) The method described in (52), where the animal is a domestic mammal, domestic fowl or cultivated fish.

(54) The agent according to any of (42) to (47), where the agent is administered orally or by injections.

(55) An agent for increasing an insulin level in breast milk, comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.

(56) The agent according to (55), where the di- or higher saccharide containing galactose is a di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.

(57) The agent according to (56), where the di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di- or higher saccharide containing N-acetylglucosamine or lactose.

(58) The agent according to (57), where the di- or higher saccharide containing N-acetylglucosamine is N-acetylglucosamine or lacto-N-neotetraose.

(59) The agent according to (57), where the di- or higher saccharide containing lactose is lacto-N-neotetraose.

globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.

(60) The agent according to (55), where the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.

(61) A food or drink with an activity to increase an insulin level in breast milk, comprising the agent according to any of (55) to (60).

(62) A feed with an activity to increase an insulin level in breast milk, comprising the agent according to any of (55) to (60).

(63) An additive for foods or drinks, which has an activity to increase an insulin level in breast milk, comprising the agent according to any of (55) to (60).

(64) An additive for feeds, which has an activity to increase an insulin level in breast milk, comprising the agent according to any of (55) to (60).

(65) A method for increasing an insulin level in breast milk in mammals, comprising administering the agent according to any of (55) to (60) to mammals or feeding a feed according to (62) to mammals.

(66) The method according to (65), where the mammals are domestic mammals.

(67) The agent according to any of (55) to (60), where the agent is administered orally or by injections.

(68) A method for promoting growth of an animal, comprising feeding breast milk from mammals administered with the agent according to any of (55) to (60) or from mammals fed with a feed according to (62).

(69) The method according to (68), where the mammals are domestic mammals.

(70) Use of the insulin secretion promoter according to any of (1) to (6) or the feed according to (9) for the preparation of a pharmaceutical composition for promoting insulin secretion in animals.

(71) Use of the insulin secretion promoter according to any of (1) to (6) or the feed according to (23) for the preparation of a pharmaceutical composition for suppressing the elevation of a blood glucose level in animals.

(72) Use of the insulin secretion promoter according to any of (1) to (6) or the feed according to (36) for the preparation of a pharmaceutical composition for ameliorating diabetes mellitus in animals.

(73) Use of the insulin secretion promoter according to any of (1) to (6) or the feed according to (49) for the preparation of a pharmaceutical composition for promoting the growth of an animal.

(74) Use of the insulin secretion promoter according to any of (1) to (6) or the feed according to (62) for the preparation of a pharmaceutical composition for increasing an insulin level in breast milk in mammals.

(75) The use of any one of (70) to (74), wherein the animals are domestic animals, domestic fowls, or cultivated fish.

(76) The use of any one of (70) to (75), wherein the pharmaceutical composition is suitable to be administered orally or by injections.

(77) The use of (74), wherein the mammals are domestic mammals.

(78) A pharmaceutical composition comprising the insulin secretion promoter according to any one of (1) to (6) or the agent according to any one of (16) to (21), (29) to (34), (42) to (47) and (55) to (60).

**[0013]** In accordance with the present invention, the insulin secretion promoter, the agent for suppressing the elevation of the blood glucose level, the agent for ameliorating diabetes mellitus, the agent for promoting growth of an animal, the agent for increasing an insulin level in breast milk or the pharmaceutical composition comprises at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as an active ingredient (sometimes herein-after referred to as "active ingredient").

**[0014]** As the di- or higher saccharide containing galactose, any galactose-containing di- or higher saccharide may be used satisfactorily. The saccharide is preferably a di- or higher saccharide containing galactose as well as N-acetylglucosamine or glucose, even more preferably a di- or higher saccharide containing N-acetylglucosamine or lactose.

**[0015]** The di- or higher saccharide containing galactose as well as N-acetylglucosamine or glucose includes, for example, N-acetylglucosamine, globotriose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, 2'-fucosyl-N-acetylglucosamine, 3'-sialyl-N-acetylglucosamine, 6'-sialyl-N-acetylglucosamine, lacto-N-tetraose, lacto-N-neotetraose, 2'-fucosyllactose-N-tetraose, 2'-fucosyllactose-N-neotetraose, 3'-sialyllactose-N-tetraose, 3'-sialyllactose-N-neotetraose, 6'-sialyllactose-N-tetraose, and 6'-sialyllactose-N-neotetraose.

**[0016]** The di- or higher saccharide containing N-acetylglucosamine includes, for example, N-acetylglucosamine, 2'-fucosyl-N-acetylglucosamine, 3'-sialyl-N-acetylglucosamine, 6'-sialyl-N-acetylglucosamine, lacto-N-neotetraose, 2'-fucosyllactose-N-neotetraose, 3'-sialyllactose-N-neotetraose, and 6'-sialyllactose-N-tetraose, and preferably includes N-acetylglucosamine and lacto-N-neotetraose.

**[0017]** The di- or higher saccharide containing lactose includes, for example, globotriose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lacto-N-tetraose, lacto-N-neotetraose, 2'-fucosyllactose-N-tetraose, 2'-fucosyllactose-N-neotetraose, 3'-sialyllactose-N-tetraose, 3'-sialyllactose-N-neotetraose, 6'-sialyllactose-N-tetraose, and 6'-sialyllactose-N-neotetraose, and preferably includes globotriose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, and lacto-N-neotetraose.

ose.

**[0018]** The saccharide containing N-acetylneuraminic acid includes, for example, N-acetylneuraminic acid, 3'-sialyllactose, 6'-sialyllactose, 3'-sialyl-N-acetylglucosamine, 6'-sialyl-N-acetylglucosamine, 3'-sialyllacto-N-tetraose, 6'-sialyllacto-N-tetraose, 3'-sialyllacto-N-neotetraose, and 6'-sialyllacto-N-neotetraose, and preferably includes N-acetylneuraminic acid, 3'-sialyllactose, and 6'-sialyllactose.

**[0019]** The saccharides can be obtained either by chemical synthetic methods, or by isolation and purification from naturally occurring substances containing the saccharides. Furthermore, the saccharides can be obtained by purchasing commercially available products.

**[0020]** Chemical syntheses of saccharides are described in "Carbohydrates in Chemistry and Biology" (B. Ernst et al., ed., Wiley-VCH, 2000). Such methods are all well known to those of ordinary skill, but representative methods are enumerated for individual saccharides.

**[0021]** Methods for producing saccharides containing galactose are described in WO98/12343. Methods for producing saccharides containing N-acetylneuraminic acid are described in USP 5,374,541. Methods for producing saccharides containing fucose are described in WO93/08205.

**[0022]** Methods for producing N-acetylglucosamine are described in WO98/12343 and Carbohydr. Res., 316, 179 (1999); methods for producing lacto-N-neotetraose are described in WO98/12343; methods for producing globotriose are described in WO98/12343 and Nat. Biotechnol., 16, 847 (1998); methods for producing 3'-sialyllactose are described in Appl. Microbiol. Biotechnol., 53, 257 (2000); methods for producing 6'-sialyllactose are described in Appl. Microbiol. Biotechnol., 53, 257 (2000); methods for producing 2'-fucosyllactose are described in J. Ind. Microbiol. Biotechnol., 25, 213 (2000); methods for producing N-acetylneuraminic acid are described in USP 5,665, 574, Carbohydr. Res., 306, 575 (1998), and EP 1,081,230.

**[0023]** Methods for isolating saccharides from naturally occurring substances are also well-known in this art and include methods using columns, see The Japanese Biochemical Society, ed., New Biochemical Experimental Series No. 3, Saccharide I, (Tokyo Kagaku Dojin), 1990. Preferable method utilizes gel filtration column chromatography and high-performance liquid chromatography.

**[0024]** All of globotriose, N-acetylglucosamine, lacto-M-neotetraose, 3'-sialyllactose, 6'-sialyllactose, 2'-fucosyllactose, and N-acetylneuraminic acid can be purchased commercially, for instance from Sigma-Aldrich.

**[0025]** The insulin secretion promoter, the agent for suppressing the elevation of blood glucose level, the agent for ameliorating diabetes mellitus, the agent for promoting growth of an animal, the agent for increasing an insulin level in breast milk or the pharmaceutical composition comprising the active ingredient according to the present invention may also contain one or more pharmacologically acceptable or comestible carriers and other effective components for therapeutic treatment if necessary.

**[0026]** The pharmaceutical preparation of the present invention can be produced by mixing the active ingredient, namely at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof, with a carrier, if necessary, by a method well known in the technical field of pharmaceuticals.

**[0027]** As the dosage regimen of the pharmaceutical preparation, an effective dosage regimen for therapeutic treatment is readily determined. Such regimen includes oral administration or parenteral administration such as intravenous administration, intraperitoneal administration, or subcutaneous administration. Among them, intravenous administration or oral administration is preferred.

**[0028]** The dosage form for administration includes, for example, tablets, powders, granules, pills, suspensions, emulsions, infusions, capsules, syrups, injections, liquids, elixirs, extracts, tincture and fluid extracts.

**[0029]** Liquid preparations suitable for oral administration, for example syrups can be prepared, using water, conventional saccharides such as sucrose, sorbitol and fructose, glycols such as polyethylene glycol and propylene glycol, oils such as sesame seed oil, olive oil and soybean oil, antiseptics such as p-hydroxybenzoate ester, preservatives such as p-hydroxybenzoate derivatives, for example p-hydroxybenzoate methyl and sodium benzoate, and other materials such as flavors, for example strawberry flavor and peppermint.

**[0030]** Further, preparations suitable for oral administration, for example tablets, powders and granules can be produced, using conventional saccharides such as lactose, sucrose, glucose, sucrose, mannitol, and sorbitol, starch such as potato, wheat and corn, inorganic materials such as calcium carbonate, calcium sulfate, sodium hydrogen carbonate, and sodium chloride, plant powders such as crystal cellulose, licorice powder and gentian powder, excipients such as pinedex, disintegrators such as starch, agar, gelatin powder, crystal cellulose, carmellose sodium, carmellose calcium, calcium carbonate, sodium hydrogen carbonate and sodium alginate, lubricants such as magnesium stearate, talc, hydrogenated vegetable oils, macrogol, and silicone oil, binders such as polyvinyl alcohol, hydroxypropyl cellulose, methyl cellulose, ethyl cellulose, carmellose, gelatin, and starch glue fluid, surfactants such as fatty acid ester, and plasticizers such as glycerin.

**[0031]** Injections suitable for parenteral administration are sterile aqueous agents comprising an active ingredient, which are preferably isotonic to the blood of an acceptor. In case of injections, for example, solutions for injection are

prepared, using carriers such as salt solutions, glucose solutions or mixtures of salt solutions and glucose solutions.

**[0032]** Even in these parenteral agents, the antiseptics, preservatives and surfactants, etc. can additionally be used.

**[0033]** The dosage dose and number of the insulin secretion promoter, the agent for suppressing the elevation of glucose level, the agent for ameliorating diabetes mellitus, the agent for promoting growth of an animal or the agent for increasing an insulin level in breast milk in accordance with the present invention vary, depending on the method of administration, the age and body weight of a patient, the nature of the symptom to be therapeutically treated, and the severity thereof. Nevertheless, in case of ordinary oral administration, the dose is generally 1 mg to 50 g per adult per day, preferably 5 mg to 20 g per adult per day once daily or in several portions daily. In case of parenteral dosing such as intravenous dosing, the dose is 0.1 mg to 50 g per adult per day, preferably 1 mg to 10 g per adult per day once daily or in several portions daily. In case of dosing to non-human animals, further, the dose varies depending on the age and species of an animal and the nature or severity of the symptom thereof. Without any specific limitation, the dose for animals is 0.1 mg to 10 g per 1 kg body weight, preferably 1 mg to 1 g per 1 kg body weight once daily or in several portions daily. In case of parenteral dosing for animals such as intravenous dosing, the dose is 0.01 mg to 10 g per 1 kg body weight, preferably 1 mg to 1 g per 1 kg body weight once daily or in several portions daily. However, these doses and the number of dosages vary depending on the individual conditions. It is further envisaged that the pharmaceutical composition of the present invention comprises any of the agents or insulin promoters mentioned herein above.

**[0034]** Furthermore, the present invention relates to a food, drink or feed with an activity to promote insulin secretion, an activity to suppress the elevation of a blood glucose level, an activity to ameliorate diabetes mellitus, an activity to promote growth of an animal or an activity to increase an insulin level in breast milk. Such food drink or feed can be produced by a general method for producing foods and drinks or feeds, including adding the active ingredient, namely at least one member selected from the group consisting of a di- or a higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof, to a raw or cooked material of the food, drink or feed.

**[0035]** The food, drink or feed in accordance with the present invention can be molded and granulated in the same manner as generally used for foods, drinks or feeds.

**[0036]** The molding and granulating method includes granulation methods such as fluid layer granulation, agitation granulation, extrusion granulation, rolling granulation, gas stream granulation, compaction molding granulation, cracking granulation, spray granulation, and injection granulation, coating methods such as pan coating, fluid layer coating, and dry coating, puff dry, excess steam method, foam mat method, expansion methods such as microwave incubation method, and extrusion methods with extrusion granulation machines and extruders.

**[0037]** The food, drink or feed according to the present invention includes foods, drinks or feeds comprising the active ingredient, namely at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, or a derivative thereof. The food, drink or feed to be used in the present invention includes any food, drink or feed. Moreover, the active ingredient, namely the di- or higher saccharide containing galactose, or a derivative thereof, or a saccharide containing N-acetylneuraminic acid, or a derivative thereof, in the food, drink or feed is not specifically limited to any concentration as long as the resulting food, drink or feed can exert an activity to promote insulin secretion, an activity to suppress the elevation of a blood glucose level, an activity to ameliorate diabetes mellitus, an activity to promote growth of an animal, or an activity to increase an insulin level in breast milk. The concentration of the active ingredient is preferably 0.001 to 100 % by weight, more preferably 0.01 to 100 % by weight and most preferably 0.1 to 100 % by weight of the food, drink or feed comprising such active ingredient.

**[0038]** Specific foods or drinks, to which the active ingredient is added, include, for example, juices, refreshing drinks, soups, teas, sour milk beverages, dairy products such as fermented milks, ices, butter, cheese, yogurt, processed milk and skim milk, meat products such as ham, sausage, and hamburger, fish meat cake products, egg products such as seasoned egg rolls and egg curd, confectioneries such as cookie, jelly, snacks, and chewing gum, breads, noodles, pickles, smoked products, dried fishes, soy sauce-seasoned boiled foods (Japanese tsukudani) and seasonings.

**[0039]** The form of the food or drink includes, for example, powder foods, sheet-like foods, bottled foods, canned foods, retort foods, capsule foods, tablet foods and fluid foods.

**[0040]** The food or drink with an activity to promote insulin secretion and the food or drink with an activity to promote growth of an infant, which are to be ingested by infants, are preferably nutritious compositions for infants. Such nutritious composition for infants includes modified milk prepared for infants, protein-decomposed milk, specific nutritionally modified milk or baby foods and foods prepared for toddlers. The form of the nutritious composition for infants includes but is not specifically limited to powder milks dried and pulverized and baby foods and also include general foods such as ice cream, fermented milk, and jelly for infantile ingestion.

**[0041]** The nutritious composition for infants in accordance with the present invention is principally composed of protein, lipid, saccharide, vitamins and/or minerals. In the nutritious composition, the active ingredient, namely at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof,



a saccharide containing N-acetylneuraminic acid, and a derivative thereof, is blended with these components.

[0042] The protein includes milk proteins such as skim milk, casein, cheese whey, whey protein concentrate and whey protein isolates, and their fractions such as  $\alpha$ -s-casein,  $\beta$ -casein,  $\alpha$ -lactoalbumin, and  $\beta$ -lactoglobulin. Further, egg protein such as egg yolk protein, egg white protein, and ovalbumin, or soybean protein such as defatted soybean protein, separated soybean protein, and concentrated soybean protein can be used. Other than these, proteins such as wheat gluten, fish meat protein, cattle meat protein and collagen may also be used satisfactorily. Further, fractions of these proteins, peptides from the acid or enzyme treatment thereof, or free amino acids may be used satisfactorily as well. The free amino acids can serve as nitrogen sources and can additionally be used to give specific physiological actions. Such free amino acids include, for example, taurine, arginine, cysteine, cystine and glutamine. The amount of such proteins, peptides or free amino acids to be blended is 5 to 30 % by weight per the total solid in a nutritious composition for infants.

[0043] The lipid includes animal fats and oils such as milk fat, lard, beef fat and fish oil, vegetable oils such as soybean oil, rapeseed oil, corn oil, coconut oil, palm oil, palm kernel oil, safflower oil, perilla oil, linseed oil, evening primrose oil, medium chain fatty acid triglyceride, and cotton seed oil, bacterially generated fats and oils, and fractionated oils thereof, hydrogenated oils thereof, and ester exchange oils thereof. The amount of lipid to be blended varies depending on the use. Preferably, the amount is 40 % by weight or less per the total solid in the nutritious composition for infants.

[0044] The saccharide includes, for example, one or more of starch, soluble polysaccharides, dextrin, monosaccharides such as sucrose, lactose, maltose, glucose, and fructose, 6'-galactosyllactose, 4'-galactosyllactose, fructooligosaccharide, lactulose, and other oligosaccharides. The total amount of such saccharide is preferably 40 to 80 % by weight to the total solid in the nutritious composition. Further, artificial sweeteners such as aspartame may be used satisfactorily. The amount of an artificial sweetener is appropriately 0.05 to 1.0 % by weight per the total solid in the nutritious composition.

[0045] The vitamins include, but are not limited to, lycopene as an essential component and additionally include, for example, vitamins such as vitamin A, vitamin B group, vitamins C, D, and E and vitamin K group, folic acid, pantothenic acid, nicotinamide, carnitine, choline, inositol and biotin as long as such vitamins can be administered to infants. Such vitamins are preferably from 10 mg to 5 g % by weight per the total solid in the nutritious composition for infants.

[0046] Further, the minerals include calcium, magnesium, potassium, sodium, iron, copper, zinc, phosphorus, chlorine, manganese, selenium and iodine. Such minerals are preferably from 1 mg to 5 g % by weight per the total solid in the nutritious composition for infants.

[0047] Other than those components described above, the nutritious composition for infants of the present invention may be blended with any component desirably blended in nutritious compositions, for example, dietary fiber, nucleotides, nucleic acids, flavors, and colorants.

[0048] The food or drink of the present invention can be used as a health food or drink or a functional food or drink to promote insulin secretion, suppress the elevation of a blood glucose level, ameliorate diabetes mellitus, promote growth of an infant or increase an insulin level in breast milk. Breast milk produced during increased insulin has a higher activity to promote growth of an infant than breast milk generally does.

[0049] When the food or drink according to the present invention is ingested, the amount to be ingested is not specifically limited. The amount to be ingested is generally 0.1 to 50 g, preferably 0.5 g to 20 g daily, based on the total amount of active ingredient. The food or drink is continuously ingested at this amount for a period from a single day up to 5 years, preferably from 2 weeks to one year. Herein, the amount ingested can be adjusted to an appropriate range depending on the severity of the symptom of the individual ingesting the food or drink, the age and body weight thereof, and the like.

[0050] The feed of the present invention may be any feed comprising the active ingredient, namely at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid and a derivative thereof, for mammals, birds, reptiles, amphibians, and fishes. The feed includes, for example, pet feeds for dogs, cats and rats, cattle feeds for cows and pigs, chicken feeds for chicken and turkeys, and fish cultivation feeds for porgy and yellowtail.

[0051] The feed can be produced by appropriately blending the active ingredient of the present invention in a raw feed material including, for example, cereals, brans, oil-seed meals, animal-derived raw feed materials, other raw feed materials and purified products.

[0052] The cereals include, for example, milo, wheat, barley, oats, rye, brown rice, buckwheat, foxtail millet, Chinese millet, Deccan grass, corn, and soybean.

[0053] The brans include, for example, rice bran, defatted rice bran, bran, lowest-grade flour, wheat germ, barley bran, screening pellet, corn bran, and corn germ.

[0054] The oil-seed meals include, for example, soybean meal, soybean powder, linseed meal, cottonseed meal, peanut meal, safflower meal, coconut meal, palm meal, sesame meal, sunflower meal, rapeseed meal, kapok seed meal and mustard meal.

[0055] The animal-derived raw feed materials include, for example, fish powders such as Hokuyo Meal, import meal,



whole meal, and coast meal, fish soluble, meat powder, meat and bone powder, blood powder, decomposed hair, bone powder, byproducts from butchery, feather meal, silkworm pupa, skim milk, casein, dry whey and krill.

[0056] Other raw feed materials include, for example, plant stems and leaves such as alfalfa, hey cube, alfalfa leaf meal, and locust leaf powder, byproducts from corn processing industries, such as corn gluten meal, corn gluten feed and corn steep liquor, starch, sugar, yeast, byproducts from fermentation industry such as beer residue, malt root, liquor residue and soy sauce residue, and agricultural byproducts such as citrus processed residue, soybean curd residue, coffee residue, and cocoa residue, cassava, horse bean, guar meal, seaweed, spirulina and chlorella.

[0057] The purified products include, for example, proteins such as casein and albumin, amino acids, starch, cellulose, saccharides such as sucrose and glucose, minerals and vitamins.

[0058] In case of providing to animals the feed according to the present invention, the amount of the feed to be ingested is not specifically limited but is 0.1 mg to 50 g per 1 kg body weight per day, preferably 0.5 mg to 20 g per 1 kg body weight per day, based on the amount of the active ingredient. The feed is continuously ingested at this amount for a period from a single day up to 5 years, preferably from 2 weeks to one year. Again, the amount ingested can be adjusted to an appropriate range depending on the species, age and body weight of the animal ingesting the feed, and the like.

[0059] Furthermore, the present invention relates to an additive for foods, drinks and feeds, to achieve an activity to promote insulin secretion, an activity to suppress the elevation of a blood glucose level, an activity to ameliorate diabetes mellitus, an activity to promote growth, or an activity to increase an insulin level in breast milk. The additive for foods or drinks includes the additive for nutritious compositions for infants.

[0060] The additive for foods, drinks or feeds has a disaccharide or a higher saccharide containing galactose, derivative thereof, a saccharide containing N-acetylneuraminic acid, or a derivative thereof as the active ingredient, can be produced by a general method for producing additives for foods, drinks or feeds. If necessary, additives for general use in foods, drinks or feeds, for example, additives described in Food Additive Handbook (The Japan Food Additives Association; issued on January 6, 1997) may be added satisfactorily, including sweeteners, colorants, preservatives, thickeners and stabilizers, anti-oxidants, color fixing agents, bleaches, antiseptics, gum base, bitters, enzymes, brightening agents, acidifier, seasonings, emulsifiers, enhancers, agents for manufacture, flavors, and spice extracts. Further, conventional saccharides, starch, inorganic materials, plant powders, excipients, disintegrators, lubricants, binders, surfactants, and plasticizers mentioned previously for pharmaceutical tablets may be added satisfactorily.

[0061] The additives include the following additives.

[0062] The sweeteners include aspartame, licorice, stevia, xylose and rakanka (Momordica grosvenori fruit). The colorants include carotenoid and turmeric oleoresin, flavonoid, caramel color, Shikon (Lithospermum erythrorhizon root) color, spirulina color, chlorophyll, purple sweet potato color, purple yam color, perilla color, and blueberry color.

[0063] The preservatives include, for example, sodium sulfite, benzoates, udo (Aralia cordata) extract, benzoin (Styrax benzoin) extract, Rumpu roman (Artemisia capillaris) extract, sorbates, and propionates. The thickeners and stabilizers include, for example, gums such as gum arabic and xanthan gum, alginates, chitin, chitosan, aloe (Aloe arborescens) extract, guar gum, hydroxypropyl cellulose, sodium casein, corn starch, carboxymethyl cellulose, gelatin, agar, dextrin, methyl cellulose, polyvinyl alcohol, microfiber cellulose, microcrystalline cellulose, seaweed cellulose, sodium polyacrylate, sodium polyphosphate, carrageenan, yeast cell wall, konjak (Amorphophallus konjac) root extract, nata de coco, and mannin.

[0064] The anti-oxidants include, for example, vitamin C group, sodium ethylenediaminetetraacetate, calcium ethylenediaminetetraacetate, erythorbic acid, oryzanol, catechin, quercetin, clove extract, enzyme-treated rutin, apple extract, sesame seed extract, dibutylhydroxytoluene, fennel extract, horseradish extract, water celery (Oenanthe javanica) extract, tea extract, tempeh extract, dokudami (Houttuynia cordata) extract, tootrienol, tocopherols, rapeseed extract, coffee bean extract, sunflower seed extract, ferulic acid, butylhydroxyanisole, blueberry leaf extract, propolis extract, hego (Cyathea feuriei)-ginkgo leaf extract, hesperetin, pepper extract, garden balsam extract, gallic acid, Chinese bayberry extract, eucalyptus extract, and rosemary extract.

[0065] The color fixing agents include, for example, sodium nitrite. The bleaches include, for example, sodium sulfite.

[0066] The antiseptics include, for example, o-phenyl phenol.

[0067] The gum base includes, for example, acetylinoleate methyl, urushi wax, ester gum, elemi resin, urucury wax, ozokerite, opopanaxresin, kaurigum, carnaubawax, guaiacresin, gutta katiau, gutta hang kang, gutta percha, glycerin fatty acid ester, spermaceti wax, copaiba balsam, copal resin, rubber, rice bran wax, cane wax, shellac, jelutong, sucrose fatty acid ester, sorva, sorbitan fatty acid ester, talc, calcium carbonate, dammar resin, chicle, chilte, Tunu, depolymerized natural rubber, paraffin wax, fir balsam, propylene glycol fatty acid ester, powdered pulp, powdered rice hulls, jojoba oil, polyisobutylene, polybutene, microcrystalline wax, mastic gum, massaranduba chocolate, bees wax and calcium phosphate.

[0068] The bitters include, for example, iso-alpha-bitter acid, caffeine, kawaratake (Coriolus versicolor) extract, red-bark cinchona extract, Phellodendron bark extract, gentian root extract, spice extracts, enzymatically modified naringin, Jamaica cassia extract, theobromine, naringin, cassia extract, absinth extract, isodonis extract, himematsutake (Agar-

icus blazei) extract, borapet, methylthioadenosine, Mannentake (Ganoderma lucidum) extract, olive tea, bitter orange (Citrus aurantium) extract, hop extract and wormwood extract.

[0069] The enzymes include, for example, amylase, trypsin, rennet and lactobacillus.

[0070] The brightening agents include, for example, urushi wax and japan wax. The acidifier include, for example, adipic acid, itaconic acid, citric acids, succinic acids, sodium acetate, tartaric acids, carbon dioxide, lactic acid, phytic acid, fumaric acid, malic acid and phosphoric acid. The seasonings include, for example, amino acids such as asparagine, aspartic acid, glutamic acid, glutamine, alanine, isoleucine, glycine, serine, cystine, tyrosine, leucine, and proline, nucleic acids such as sodium inosinate, sodium uridinate, sodium guanylate, sodium cytidylate, calcium ribonucleotide and sodium ribonucleotide, organic acids such as citric acid and succinic acid, potassium chloride, sodium chloride-decreased brine, crude potassium chloride, whey salt, tripotassium phosphate, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, disodium hydrogen phosphate, sodium dihydrogen phosphate, trisodium phosphate and chlorella extract.

[0071] The enhancers include, for example, zinc salts, vitamin C group, various amino acids, 5-adenylic acid, iron chloride, hesperidin, various calcined calcium, various non-calcined calcium, dibenzoylthiamine, calcium hydroxide, calcium carbonate, thiamine hydrochloride salt, Dunaliella carotene, tocopherol, nicotinic acid, carrot carotene, palm oil carotene, calcium pantothenate, vitamin A, hydroxyproline, calcium dihydrogen pyrophosphate, ferrous pyrophosphate, ferric pyrophosphate, ferritin, heme iron, menaquinone, folic acid and riboflavine.

[0072] The agents for manufacture include, for example, processing auxiliaries such as acetone and ion exchange resin, Fig leaf extract, rice straw ash extract, kaolin, glycerin fatty acid ester, mulberry extract, bone ash, Perilla extract, ginger extract, various tannins, paffia extract, grape seed extract, and ethanol.

[0073] The flavors include, for example, vanilla essence and the spice extracts include, for example, capsicum extract.

[0074] These various additives can be added to the active ingredient, taking into consideration the mode of administration, in accordance with the present invention.

[0075] It is possible in humans or animals to promote insulin secretion. suppress the elevation of a blood glucose level, ameliorate diabetes mellitus, promote growth or increase an insulin level in breast milk, by dosing with the active ingredient. Additionally, the growth of infants can be promoted by administration of breast milk containing the increased insulin to human or animal infants.

[0076] The present invention will now be described below with reference to the following examples. However, the examples do not limit the scope of the present invention.

#### Example 1

Production of an insulin secretion promoter comprising 2'-fucosyllactose

[0077] An insulin secretion promoter of the following composition was produced by mixing the individual components together.

2'-Fucosyllactose	49 g
Pinedex #3 (excipient; Matsutani Chemical Industry, Co., Ltd.)	49 g
Ferric pyrophosphate (iron source)	0.1 g
PhosCal EFC (calcium source; Nikko Fine Product, Co.)	1 g
Vitamin mix (Merck Co.)	1 g

#### Example 2

Production of an insulin secretion promoter comprising N-acetylneuraminic acid

[0078] An insulin secretion promoter of the following composition was produced by mixing the individual components together.

N-Acetylneuraminic acid	49 g
Pinedex #3 (excipient; Matsutani Chemical Industry, Co., Ltd.)	49 g
Ferric pyrophosphate (iron source)	0.1 g
PhosCal EFC (calcium source; Nikko Fine Product, Co.)	1 g
Vitamin mix (Merck Co.)	1 g

Example 3

Production of an insulin secretion promoter comprising 2'-fucosyllactose and N-acetylneuraminic acid

[0079] 2'-Fucosyllactose (10 g) and N-acetylneuraminic acid (10 g) were dispersed in 180 ml of water, to produce an insulin secretion promoter.

Example 4

Production of 2'-fucosyllactose-comprising cake

[0080] Cookies (30 pieces) were produced from the following blend.

Cake flour	100 g
Starch	74 g
Water	14 g
2'-Fucosyllactose	30 g
Baking powder	2 teaspoons
Salt	2 teaspoons
Egg	one egg
Butter	80 g
Milk	2 tablespoons

Example 5

Production of N-acetylneuraminic acid-comprising cake

[0081] Cookies (30 pieces) were produced from the following blend.

Cake flour	100 g
Starch	74 g
Water	14 g
N-Acetylneuraminic acid	30 g
Baking powder	2 teaspoons
Salt	2 teaspoons
Egg	one egg
Butter	80 g
Milk	2 tablespoons

Example 6

Production of 2'-fucosyllactose-comprising modified powder milk

[0082] The modified powder milk for infants of the following composition was produced.

2'-Fucosyllactose	20 g
Skim milk	5.04 kg
Whey protein concentrate	158 g
Lactose	924 g
Water-soluble vitamin mixture	75 g
Minerals	75 g
Lipophilic vitamin	578 g

[0083] These components and homogenized together, sterilized by a routine method, concentrated and dried, to

produce a modified milk.

### Test Example 1

#### 5 Activity of 2'-fucosyllactose to promote insulin secretion (1)

[0084] Male 9-week-old C57BL/KsJ-db/db Jcl (abbreviated as "db/db" hereinafter) mice (Clea Japan, Inc.), which are model animals of Type II diabetes mellitus, were divided in groups each consisting of 6 mice, and fed a commercially available feed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment.

10 [0085] After acclimation, an aqueous 10 % solution of 2'-fucosyllactose (sometimes abbreviated as "2'-FL" hereinafter) was orally administered to the mice at 200 mg (2'-FL) /kg body weight in the morning and at 300 mg (2'-FL) /kg body weight in the evening. The same volume of Saline was administered to the control group. The aqueous 2'-FL solution and the saline were both dosed daily to the mice for 7 days.

[0086] During the dosing period, CE-2 was given together with drinking water ad libitum.

15 [0087] After 18-hour starvation from the final dosing on day 7, an aqueous 40 % glucose solution was orally administered to 2 g (glucose) /kg body weight to the mice, to perform glucose tolerance test. Zero minute and 30 minutes after glucose loading, blood was taken from tail vein. 120 minutes thereafter, the mice were anesthetized with sodium pentobarbital at 50 mg/kg body weight, to collect the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

20 [0088] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for rats-T) (Shibayagi, Co., Ltd.) as follows. The kit reacts with insulin in the sera of both rats and mice.

[0089] First, the serum recovered was diluted with the buffer attached to the kit to 5 fold. 10 µl of the diluted serum was taken and divided in the wells of the antibody-immobilized plate into which 100 µl of a biotin-bound anti-insulin antibody was added, for reaction at ambient temperature for 2 hours. After the reaction, the plate was rinsed four times with the rinse solution attached to the kit. After rinsing, 100 µl of the peroxidase-avidin bound material was divided in the wells, for reaction at ambient temperature for 30 minutes. After reaction, the plate was rinsed four times with the rinse solution. After rinsing, 100 µl of the chromogenic solution was divided in the wells, for chromogenic reaction for 30 minutes, followed by addition of 100 µl of the reaction termination solution to each well. The absorbance of the reaction solution in the wells at 450 nm was read with a plate reader.

25 [0090] Herein, a standard curve was prepared by using the 200 ng/ml standard insulin solution (rat) attached to the kit as a standard solution to dilute the standard solution appropriately with the buffer solution attached to the kit for the same reaction as for the serum, and plotting the relation between the concentration and the absorbance (450 nm).

[0091] Based on the prepared standard curve and the absorbance from the reaction with the serum, the insulin concentration in the serum was determined. The results are shown in Table 1.

Table 1

Serum insulin concentration after glucose loading				
Groups	N	Insulin concentration (ng/ml)		
		Zero minute	30 minutes	120 minutes
Control group	6	5.4 ± 1.7	4.8 ± 2.5	12.6 ± 6.0
2'-FL group	6	6.7 ± 3.3	8.3 ± 3.9	26.1 ± 12.8
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).				

[0092] Table 1 shows that the insulin concentration after glucose loading in the db/db mice was increased via the continuous daily oral dosing of 2'-FL with the elapse of time, compared with the control group, indicating that insulin secretion was promoted.

### Test Example 2

#### Activity of 2'-fucosyllactose to promote insulin secretion (2)

55 [0093] Eleven male 9-week-old ICR mice as normal mice (SLC, Inc.) were fed a commercially available CE-2 (Clea Japan, Inc.) for one week, so as to accustom the mice to the environment.

[0094] After acclimation, an aqueous 10 % solution of 2'-fucosyllactose was orally administered to the mice at 200

mg (2'-FL) /kg body weight in the morning and at 300 mg (2'-FL) /kg body weight in the evening. The same volume of saline was administered to the control group. The aqueous 2'-FL solution and saline were both dosed daily to the mice for 7 days.

[0095] During the dosing period, CE-2 was given together with drinking water ad libitum.

[0096] After 18-hour starvation from the final dosing on day 7, an aqueous 40 % glucose solution was orally administered to 2 g (glucose)/kg body weight to the mice, to perform glucose tolerance test. Zero minute after glucose loading, blood was taken from a tail vein. 120 minutes thereafter, additionally, the mice were anesthetized with sodium pentobarbital at 50 mg/kg body weight, to draw the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

[0097] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for mice-T) (Shibayagi, Co., Ltd.). 10 µl of the serum was taken and divided in the wells of the antibody-immobilized plate into which 100 µl of a biotin-bound anti-insulin antibody was added, for reaction at ambient temperature for 2 hours. After the reaction, the plate was rinsed four times with the rinse solution attached to the kit. After rinsing, 100 µl of the peroxidase-avidin bound material was divided in the wells, for reaction at ambient temperature for 30 minutes.

[0098] After the reaction, the plate was rinsed four times with the rinse solution. After rinsing, 100 µl of the chromogenic solution was divided in the wells, for chromogenic reaction for 30 minutes, followed by addition of 100 µl of the reaction termination solution to each well. The absorbance of the reaction solution in the wells at 450 nm was read with a plate reader. Herein, a standard curve was prepared by using the standard insulin solution (mice, 200 ng/ml) attached to the kit as a standard solution to dilute the standard solution appropriately with the buffer solution attached to the kit for the same reaction as for the serum, and plotting the relation between the concentration and the absorbance (450 nm). Based on the prepared standard curve and the absorbance from the reaction with the serum, the insulin concentration in the serum was determined. The results are shown in Table 2.

Table 2

Serum insulin concentration after glucose loading			
Groups	N	Insulin concentration (ng/ml)	
		Zero minute	120 minutes
Control group	5	ND	0.27 ± 0.13
2'-FL group	6	ND	0.35 ± 0.24
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).			
ND means no insulin detection.			

[0099] Table 2 shows that the insulin concentration 120 minutes after glucose loading in the ICR mice was increased via the continuous daily oral dosing of 2'-FL, compared with the control group, indicating that insulin secretion was promoted.

### Test Example 3

#### Activity of various saccharides to promote insulin secretion (1)

[0100] Group of male 9-week-old db/db mice (Clea Japan, Inc.) each consisting of 6 mice were fed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment.

[0101] After acclimation, individual aqueous 10 % solutions of globotriose (abbreviated "globo" hereinafter), N-acetyl-lactosamine (abbreviated as "LacNac" hereinafter) and N-acetylneuraminic acid (abbreviated as "NeuAc" hereinafter) were orally administered to the mice at 200 mg (saccharide) /kg body weight in the morning and at 300 mg (saccharide) /kg body weight in the evening.

[0102] The same volume of saline was administered to the control group. The individual aqueous saccharide solutions and saline were both dosed daily to the mice for 7 days. During the dosing period, CE-2 was given together with drinking water ad libitum.

[0103] On day 8, the whole blood was collected from the inferior vena cava of the mice under anesthesia with sodium pentobarbital at 50 mg/kg body weight. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

[0104] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for rats-T) (Shibayagi, Co., Ltd.) in the same manner as in the Test Example 1. The results are shown in Table 3.

Table 3

Serum insulin concentration after dosing of the individual saccharides		
Groups	N	Insulin concentration (ng/ml)
Control group	6	12.4 ± 5.9
Globo group	6	23.7 ± 16.4
LacNac group	6	26.8 ± 11.5
NeuAc group	6	68.4 ± 45.9
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).		

[0105] Table 3 shows that the serum insulin concentration in the db/db mice was increased via the continuous daily oral dosing of globo, LacNac or NeuAc, compared with the control group, indicating that insulin secretion was promoted.

#### Test Example 4

Activity of various saccharides to promote insulin secretion (2)

[0106] Groups of male 9-week-old db/db mice (Clea Japan, Inc.) each consisting of 6 mice were fed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment.

[0107] After acclimation, individual aqueous 10 % solutions of 3'-sialyllactose (abbreviated as "3'-SL" hereinafter), 6'-sialyllactose (abbreviated as "6'-SL") and 2'-FL were orally administered to the mice at 200 mg (saccharide) /kg body weight in the morning and at 300 mg (saccharide) /kg body weight in the evening. The both volume of saline was administered to the control group. The individual aqueous saccharide solutions and saline were both dosed daily to the mice for 7 days. During the dosing period, CE-2 was given together with drinking water ad libitum.

[0108] After 18-hour starvation from the final dosing on day 7, an aqueous 40 % glucose solution was orally administered to 2 g (glucose) /kg body weight to the mice, to perform glucose tolerance test. Zero minute and 30 minutes after glucose loading, blood was taken from a tail vein, 120 minutes thereafter, further, the mice were anesthetized with sodium pentobarbital at 50 mg/kg body weight, to collect the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for rats-T) (Shibayagi, Co., Ltd.) in the same manner as in the Test Example 1. The results are shown in Table 4.

Table 4

Serum insulin concentration after glucose loading				
Groups	N	Insulin concentration (ng/ml)		
		Zero minute	30 minutes	120 minutes
Control group	6	5.4 ± 1.7	4.8 ± 2.5	12.6 ± 6.0
3'-SL group	6	6.0 ± 2.2	5.1 ± 1.9	22.0 ± 12.5
6'-SL group	6	5.9 ± 3.0	6.6 ± 3.4	17.9 ± 6.3
2'-FL group	6	6.7 ± 3.3	8.3 ± 3.9	26.1 ± 12.9
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).				

[0109] Table 4 shows that the serum insulin concentration during glucose loading in the db/db mice was increased via the continuous daily oral dosing of 3'-SL, 6'-SL or 2'-FL, compared with the control group, indicating that insulin secretion was promoted.

Test Example 5

Activity of various saccharides to promote insulin secretion (3)

[0110] Groups of male 9-week-old db/db mice (Clea Japan, Inc.) each consisting of 6 mice were fed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment.

[0111] After acclimation, individual aqueous 10 % solutions of lacto-N-neotetraose (abbreviated as "LNnT" hereinafter) and NeuAc were orally administered to the mice at 200 mg (saccharide) /kg body weight in the morning and at 300 mg (saccharide) /kg body weight in the evening. The same volume of saline was administered to the control group. The individual aqueous saccharide solutions and saline were both dosed daily to the mice for 7 days. During the dosing period, CE-2 was given together with drinking water ad libitum.

[0112] After 18-hour starvation from the final dosing on day 7, an aqueous 40 % glucose solution was orally administered to 2 g (glucose) /kg body weight to the mice, to perform glucose tolerance test. Zero minute and 30 minutes after glucose loading, blood was taken from a tail vein, 120 minutes thereafter, further, the mice was anesthetized with sodium pentobarbital at 50 mg/kg body weight, to collect the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

[0113] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for rats-T) (Shibayagi, Co., Ltd.) in the same manner as in the Test Example 1. The results are shown in Table 5.

Table 5

Serum insulin concentration after glucose loading				
Groups	N	Insulin concentration (ng/ml)		
		Zero minute	30 minutes	120 minutes
Control group	6	11.2 ± 7.8	10.6 ± 3.7	17.4 ± 10.2
LNnT group	6	8.9 ± 2.0	21.7 ± 13.8	25.9 ± 13.2
NeuAc group	6	8.9 ± 7.7	18.5 ± 8.5	30.3 ± 10.7
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).				

[0114] Table 5 shows that the insulin concentration during glucose loading in the db/db mice was increased via the continuous daily oral dosing of LNnT or NeuAc, compared with the control group, indicating that insulin secretion was promoted.

Test Example 6

[0115] Activity of various saccharides to promote insulin secretion in blood and activity thereof to suppress the elevation of blood glucose level

[0116] Groups of male 9-week-old ICR mice (Japan SLC, Inc.) each consisting of 7 mice were fed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment. Then, the mice were fasted for 18 hours.

[0117] An aqueous 10 % solution of 2'-FL or NeuAc was intravenously administered to the mice to 500 mg (saccharide) /kg body weight, while an aqueous 40 % glucose solution was orally administered simultaneously to 2 g (glucose) /kg body weight to the mice. To the control group, physiological saline was administered intravenously, while glucose was orally administered simultaneously to 2g/kg body weight. Zero minute and 30 minutes after glucose loading, blood was taken from a tail vein. 120 minutes thereafter, the mice were anesthetized with sodium pentobarbital at 50 mg/kg body weight, to collect the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum.

[0118] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for mice-T) (Shibayagi, Co., Ltd.) in the same manner as in the Test Example 2.

[0119] Furthermore, the glucose concentration in the serum recovered was also assayed. The glucose concentration was assayed, using Glucose CII-TEST WAKO (WAKO Pure Chemical Industries, Ltd.). 2 µl of the recovered serum was placed in a 96-well plate, followed by addition of 200 µl of the chromogenic solution attached to the kit, for incubation at 37 °C for 10 minutes. After incubation, the absorbance at 490 nm was assayed with a plate reader. Herein, a standard curve was prepared by using aqueous 500 mg/dl glucose solution as the standard solution to dilute the standard solution appropriately for the same reaction as for the serum, and plotting the relation between the concentration and the absorbance (490 nm). Based on the prepared standard curve and the absorbance from the reaction with the serum,



the glucose concentration in the serum was determined.

[0120] The serum insulin concentration and the serum glucose concentration are shown in Table 6 and Table 7, respectively.

Table 6

Serum insulin concentration after glucose loading				
Groups	N	Insulin concentration (pg/ml)		
		Zero minute	30 minutes	120 minutes
Control group	7	ND	161.3 ± 67.9	258.6 ± 308.9
2'-FL group	7	ND	192.3 ± 57.4	2090.7 ± 533.1
NeuAc group	7	ND	178.3 ± 105.5	384.4 ± 394.1
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).				
ND means no detection.				

Table 7

Serum glucose concentration after glucose loading				
Groups	N	Glucose concentration (mg/dl)		
		Zero minute	30 minutes	120 minutes
Control group	7	109.7 ± 17.9	377.2 ± 107.2	240.2 ± 50.7
2'-FL group	7	102.4 ± 23.3	331.4 ± 68.6	169.2 ± 29.5
NeuAc group	7	102.6 ± 12.1	300.9 ± 101.6	197.6 ± 28.8
The numerical figure of the glucose concentration is shown in (mean ± standard deviation).				

[0121] Table 6 and Table 7 show that the serum insulin concentration after glucose loading in the ICR mice was increased via the intravenous dosing of 2'-FL or NeuAc, compared with the control group, indicating that insulin secretion was promoted and that the increase of the serum glucose concentration was suppressed as the insulin concentration increased, compared with the control group, indicating that the elevation of the blood glucose level was suppressed.

#### Test Example 7

Activity of 2'-fucosyllactose to promote insulin secretion (3)

[0122] Groups of male 9-week-old ICR mice (Japan SLC, Inc.) each consisting of 7 mice were fed a commercially available CE-2 (Clea Japan, Inc.) for one week, so as to accustom the mice to the environment. Thereafter, an aqueous 1 % solution of 2'-FL was intravenously administered to the mice to 50 mg (2'-FL) /kg body weight. The same volume of saline was administered to the control group. Zero minute and 30 minutes after dosing, blood was taken from a tail vein. 120 minutes thereafter, the mice was anesthetized with sodium pentobarbital at 50 mg/kg body weight, to collect the whole blood from inferior vena cava. Blood was centrifuged (4 °C, 10000 rpm, 10 minutes), to obtain serum,

[0123] Insulin in the serum recovered was assayed by enzyme immunoassay using Lebis Insulin kit (for mice-T) (Shibayagi, Co., Ltd.) in the same manner as in the Test Example 2. The results are shown in Table 8.

Table 8

Serum insulin concentration after 2'-FL dosing				
Groups	N	Insulin concentration (pg/ml)		
		Zero minute	30 minutes	120 minutes
Control group	7	ND	ND	ND

Table 8 (continued)

Serum insulin concentration after 2'-FL dosing				
Groups	N	Insulin concentration (pg/ml)		
		Zero minute	30 minutes	120 minutes
2'-FL group	7	ND	168.6 ± 40.2	2035.9 ± 1098.0
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).				
ND means no detection.				

[0124] Table 8 shows that the serum insulin concentration in the ICR mice was increased via the intravenous 2'-FL dosing, compared with the control group, indicating that insulin secretion was promoted.

#### Test Example 8

Actions of 2'-fucosyllactose to promote insulin secretion and to suppress the elevation of blood glucose level

[0125] Groups of male 8-week-old ICR mice (Japan SLC, Inc.) each consisting of 6 mice were fed CE-2 (Clea Japan, Inc.) for one week, so as to accustom the animals to the environment.

[0126] Then, the mice accustomed were fasted for 18 hours. An aqueous 2 % solution of 2'-FL was orally administered to the mice to 100 mg (2'-FL) /kg body weight, while 0.9 % saline was administered orally to the control group. Two hours after the 2'-FL dosing, an aqueous 40 % glucose solution was orally administered to 2 g (glucose) /kg body weight to the mice, for glucose tolerance test. Zero minute, 30 minutes and 120 minutes after glucose loading, blood was taken from a tail vein. Blood glucose was assayed with a simple-type blood glucose assay apparatus Medisafe Reader GR-101 (Terumo, Co., Ltd.), while the serum was collected.

[0127] Insulin in the serum recovered was assayed by enzyme immunoassay using Morinaga ultra-sensitive rat insulin assay kit (Morinaga Biochemical Research Institute, Co., Ltd.) described below. 15 µl of the serum was divided in the wells of an antibody-immobilized plate, where 85 µl of the diluent attached to the kit was divided therein, for reaction at 4 °C for 2 hours. After the reaction, the plate was rinsed five times with the rinse solution attached to the kit. After rinsing, 100 µl of an enzyme-labeled guinea pig anti-rat insulin antibody was divided in each well, for reaction at ambient temperature for 30 minutes. After the reaction, the plate was rinsed seven times with the rinse solution. After rinsing, 100 µl of the enzyme substrate solution was divided in the wells. for chromogenic reaction for 30 minutes, followed by addition of 100 µl of the reaction termination solution to each well. The absorbance of each well at 450 nm (principal wave length) and 655 nm (sub wave length) was measured with BioRad Model 3550 microplate reader (BioRad Laboratories, Inc.). Additionally, a standard curve was prepared by diluting 2 ng of the standard insulin (mouse) attached to the kit with 100 µl of saline to use the resulting 20 ng/ml insulin solution as the standard solution, diluting the standard solution appropriately with the diluent attached to the kit for the same reaction as for the serum. and plotting the relation between the concentration and the absorbance at the principal wave length of 450 nm and at the sub wave length of 655 nm. Based on the prepared standard curve, the serum insulin concentration corresponding to the absorbance during the reaction with the serum was determined. The results are shown in Tables 9 and 10.

Table 9

Serum blood glucose level after glucose loading					
Groups	N	Blood glucose level (mg/dl)			
		-120 minutes	0 minute	60 minutes	120 minutes
Control group	6	123.3 ± 25.4	118.2 ± 14.8	251.0 ± 53.8	159.5 ± 18.7
2'-FL group	6	131.4 ± 23.6	108.6 ± 4.4	218.9 ± 29.0	147.3 ± 14.2
Blood glucose is shown in (mean ± standard deviation).					

Table 10

Serum insulin concentration 60 minutes after glucose loading		
Groups	N	Insulin concentration (pg/ml)
Control group	6	26.4 ± 33.4
2'-FL group	6	82.6 ± 91.7
The numerical figure of the insulin concentration is shown in (mean ± standard deviation).		

[0128] Table 9 and Table 10 show that the serum insulin concentration 60 minutes after glucose loading in the ICR mice was increased via the single oral dosing of 2'-FL 120 minutes before glucose dosing, compared with the control group, indicating that insulin secretion was promoted and that the elevation of blood glucose level was suppressed.

#### Test Example 9

Activity of 2'-fucosyllactose to promote insulin secretion in Type I diabetes mellitus model animal

[0129] Male 7-week-old Wistar rats (Japan SLC, Inc.) were fed CE-2 (Clea Japan, Inc.) for one week, so as to acustom the rats to the environment.

[0130] After 18-hour starvation of the accustomed rats, 300 ml of 50 mM citrate buffer, pH 4.5 containing 15 mg of streptozotocin (WAKO Pure Chemical Industries, Inc.; abbreviated as "STZ" hereinafter) was prepared and administered to 25 mg (STZ)/kg body weight from their tail vein. Five days after the STZ administration, the rats were fasted for 18 hours. Blood was taken from puncture in the tail vein to assay blood glucose with a simple-type blood glucose assay apparatus Medisafe Reader GR-101 (Terumo, Co., Ltd.), to select 5 rats (Nos. 1, 3, 4, 5, 8) at mild state of diabetes mellitus with a blood glucose level of 200 mg/dl or less.

[0131] An aqueous 2 % solution of 2'-fucosyllactose was prepared and administered to the rat No.1 from the tail vein to 50 mg/kg body weight on a 2'-FL dose basis. 0.9 % physiological saline was administered to rats Nos. 3, 4, 5 and 8. Two hours after 2'-FL dosing, an aqueous 40 % glucose solution was orally administered to 1 g/kg body weight to the rats for glucose tolerance test. Zero minute and 30, 60, 120, and 240 minutes after glucose loading, blood was taken from a tail vein, to assay blood glucose with Medisafe Reader GR-101 and collect the serum.

[0132] 12 days after the STZ dosing, the rats were fasted for 18 hours. An aqueous 2 % solution of 2'-FL at 50 mg (2'-FL) /kg body weight was administered to rats Nos. 3, 4, 5 and 8 on a 2'-FL dose basis through their tail veins. To the rat No.1 was administered 0.9 % physiological saline. Two hours after 2'-FL dosing, an aqueous 40 % glucose solution was orally administered to 1g (glucose) /kg body weight to the rats, for glucose tolerance test. Zero minute and 30, 60, 120, and 240 minutes after glucose loading, blood was taken from a tail vein, to assay blood glucose with Medisafe Reader GR-101 and collect the serum.

[0133] Insulin in the serum was assayed by enzyme immunoassay using Morinaga ultra-sensitive rat insulin assay kit (Morinaga Biochemical Research Institute, Co., Ltd.) in the same manner as in Test Example 8. Additionally, a standard curve was prepared by diluting 2.56 ng of the standard insulin (rat) attached to the kit with 100 µl of saline to use the resulting 25.6 ng/ml insulin solution as the standard solution, diluting the standard solution appropriately with the diluent attached to the kit for the same reaction as for the serum, and plotting the relation between the concentration and the absorbance at the principal wave length of 450 nm and at the sub wave length of 655 nm. Based on the prepared standard curve, serum insulin corresponding to the absorbance during the reaction with the serum was determined. The results are shown in Tables 11 and 12.

Table 11

Serum insulin concentration			
Rat Nos.	Dosed substance	Serum insulin concentration (pg/ml)	
		0 minute	30 minutes
1	Saline	10.2	43.1
	2'-FL	180.4	475.5

Table 11 (continued)

Serum insulin concentration			
Rat Nos.	Dosed substance	Serum insulin concentration (pg/ml)	
		0 minute	30 minutes
3	Saline	57.0	120.8
	2'-FL	312.5	148.4
4	Saline	148.4	98.7
	2'-FL	125.8	331.1
5	Saline	81.9	86.7
	2'-FL	697.0	586.6
8	Saline	229.4	329.7
	2'-FL	197.4	915.1

Table 12

Blood glucose level after glucose loading							
Rat Nos.	Dosed substance	Blood glucose level (mg/dl)					
		-120 minutes	0 minute	30 minutes	60 minutes	120 minutes	240 minutes
1	Saline	120	110	195	278	254	176
	2'-FL	117	138	152	158	136	50
3	Saline	120	175	276	315	325	277
	2'-FL	108	135	167	172	181	146
4	Saline	167	168	245	285	348	310
	2'-FL	197	186	273	355	342	328
5	Saline	115	119	215	220	158	112
	2'-FL	122	97	237	253	224	139
8	Saline	117	116	198	275	249	185
	2'-FL	121	134	162	154	161	139

[0134] Table 11 and Table 12 show that the serum insulin concentration was increased via glucose loading 2 hours after the intravenous dosing of 2'-FL to the STZ-induced diabetic rats, indicating that insulin secretion was promoted and that the increase of blood glucose level was suppressed.

#### Industrial Applicability

[0135] The present invention provides an insulin secretion promoter, an agent for suppressing the elevation of a blood glucose level, a diabetes mellitus-ameliorating agent, a growth promoter, and an agent for increasing insulin in breast milk, a food or drink or a feed, with an action to increase insulin secretion, an action to suppress blood glucose increase, an action to ameliorate diabetes mellitus, an action to promote growth, or an action to increase insulin in breast milk, an additive for foods and drinks or an additive for feeds, with an action to increase insulin secretion, an action to suppress blood glucose increase, an action to ameliorate diabetes mellitus, an action to promote growth, or an action to increase insulin in breast milk.

## Claims

1. An insulin secretion promoter, comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, or a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.
2. An agent for suppressing the elevation of a blood glucose level comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.
3. An agent for ameliorating diabetes mellitus comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.
4. An agent for promoting growth of an animal comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.
5. An agent for increasing an insulin level in breast milk, comprising at least one member selected from the group consisting of a di- or higher saccharide containing galactose, a derivative thereof, a saccharide containing N-acetylneuraminic acid, and a derivative thereof as the active ingredient.
6. The insulin secretion promoter according to claim 1 or the agent according to anyone of claims 2 to 5, wherein the di- or higher saccharide containing galactose is a di- or a higher saccharide containing galactose and additionally N-acetylglucosamine or glucose.
7. The insulin secretion promoter or the agent according to any one of claims 1 to 6, wherein the di- or higher saccharide containing galactose and additionally N-acetylglucosamine or glucose is a di- or higher saccharide containing N-acetylglucosamine or lactose.
8. The insulin secretion promoter or the agent according to claim 7, wherein the di- or higher saccharide containing N-acetylglucosamine is N-acetylglucosamine or lacto-N-neotetraose.
9. The insulin secretion promoter or the agent according to claim 7, wherein the di- or higher saccharide containing lactose is lacto-N-neotetraose, globotriose, 3'-sialyllactose, 6'-sialyllactose or 2'-fucosyllactose.
10. The insulin secretion promoter according to claim 1 or the agent according to any one of claims 2 to 5, wherein the saccharide containing N-acetylneuraminic acid is 3'-sialyllactose, 6'-sialyllactose or N-acetylneuraminic acid.
11. A food, drink or feed or an additive for foods, drinks or feeds with an activity to promote insulin secretion, comprising the insulin secretion promoter according to any one of claims 1 and 6 to 10.
12. The additive for foods, or drinks or feed according to claim 11, wherein the food or drinks is a nutritious composition or is an additive for nutritious compositions for infants.
13. A food, drink, or feed or an additive for foods, drinks or feeds with an activity to suppress the elevation of a blood glucose level, comprising the agent according to any one of claims 2 and 6 to 10.
14. A food, drink, or feed or an additive for foods, drinks or feeds, which has an activity to ameliorate diabetes mellitus, comprising the agent according to any one of claims 3 and 6 to 10.
15. A nutritious composition for infants, a feed or an additive for nutritious compositions for infants or animals or for feeds with an activity to promote growth of an infant or an animal, comprising the agent according to any one of claims 4 and 6 to 10.
16. A food, drink or feed or an additive for foods, drinks or feeds with an activity to increase an insulin level in breast milk, comprising the agent according to any one of claims 5 to 10.

17. Use of the insulin secretion promoter according to any one of claims 1 and 6 to 10 or the feed according to claim 11 for the preparation of a pharmaceutical composition for promoting insulin secretion in animals.
18. Use of the agent according to any one of claims 2 and 6 to 10 or the feed according to claim 13 for the preparation of a pharmaceutical composition for suppressing the elevation of a blood glucose level in animals.
19. Use of the agent according to any one of claims 3 and 6 to 10 or the feed according to claim 14 for the preparation of a pharmaceutical composition for ameliorating diabetes mellitus in animals.
20. Use of the agent according to any one of claims 4 and 6 to 10 or the feed according to claim 15 for the preparation of a pharmaceutical composition for promoting the growth of an animal.
21. Use of the agent according to any one of claims 5 to 10 or the feed according to claim 16 for the preparation of a pharmaceutical composition for increasing an insulin level in breast milk in mammals.
22. The use according to any one of claims 17 to 20, wherein the animals are domestic animals, domestic fowls, or cultivated fish.
23. The use according to any one of claims 17 to 21, wherein said pharmaceutical composition is suitable to be orally administered or by injections.
24. A method for promoting growth in animals, comprising feeding breast milk from a mammal administered with the agent according to any of claims 5 to 10 or from a mammal fed with a feed according to claim 16.
25. The use according to claim 21 or the method according to claim 24, wherein the mammal is a domestic mammal.
26. A pharmaceutical composition comprising the insulin secretion promoter of any one of claims 1 and 6 to 10 or the agent of any one of claims 2 to 5.



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 03 00 2166 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 01 78748 A (MITSUHIRO OKANO ; TERRAZAS LUIS IGNACIO (US); HARN DONALD A (US); H) 25 October 2001 (2001-10-25) * claims 1,6,7,14-17 *	1-9, 11-23, 25,26	A61K31/7016 A61K31/702 A61K31/7012 A23L1/09 A23L1/30
Y	* page 16, line 4-26 *	10,24	
X	US 5 164 374 A (RADEMACHER THOMAS W ET AL) 17 November 1992 (1992-11-17) * claims 1-9 * * table 1 * * column 3, line 65-68 * * column 4, line 1-8 * * column 5, line 3-68 *	1-7,9, 10,26	
Y	* column 9, line 1-10 *	10,24	
X	US 5 177 062 A (MIYATA TAKESHI ET AL) 5 January 1993 (1993-01-05) * claims 1-5 *	1-6,10, 26	
Y	* column 2, line 25-68 *	10,24	
X	US 5 639 734 A (ESKO JEFFREY D ET AL) 17 June 1997 (1997-06-17) * claims 1,2,12-16 *	1-10,26	
	---		TECHNICAL FIELDS SEARCHED (Int.Cl.7)
	-/--		A61K A23L A61P
<b>INCOMPLETE SEARCH</b>			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
MUNICH		30 May 2003	Schifferer, H
CATEGORY OF CITED DOCUMENTS		<p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>	
<p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p>			

EPO FORM 1503 03.82 (P04C07)





European Patent  
Office

INCOMPLETE SEARCH  
SHEET C

Application Number  
EP 03 00 2166

Claim(s) searched completely:

Claim(s) searched incompletely:  
1-26

Reason for the limitation of the search:

Present claims 1-16 and 26 relate to an extremely large number of possible compounds, since the description of the compounds includes not only disaccharides, but also higher saccharides which may contain galactose or a saccharide with N-acetylneuraminic acid and further any derivative thereof.

In fact, -based on this - the claims contain so many options that a lack of clarity (and conciseness) within the meaning of Article 84 EPC arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear (and concise), namely the concrete examples of compounds which are disclosed in the application (see description pages 14 and 15, further test examples 1 to 9):

N-acetyllactosamine, globotriose, 2'-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, 2'-fucosyl-N-acetyllactosamine, 3'-sialyl-N-acetyllactosamine, 6'-sialyl-N-acetyllactosamine, lacto-N-tetraose, lacto-N-neotetraose, 3'-sialyllacto-N-neotetraose, N-acetylneuraminic acid, N-acetylglucosamine.

In addition, present claims 17-25, which are to be considered as second medical use claims, relate to a therapeutic application which is functionally defined by the pharmacodynamic mechanism of action and the pharmacokinetic results, namely:

"promoting insulin secretion",  
"suppressing the elevation of a blood glucose level",  
"promoting the growth of an animal", and  
"increasing an insulin level in breast milk in mammals".

The claims cover all therapeutic use having this characteristic or property, whereas the application provides support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC for only a very limited number of such therapeutic use. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC). An attempt is made to define the therapeutic application by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the objective "to ameliorate, prevent or therapeutically treat diabetes mellitus via daily intake" (see description, page 3, lines 23-24).



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 03 00 2166

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 00 32205 A (HARN DONALD A ; HARVARD COLLEGE (US)) 8 June 2000 (2000-06-08) * claims 1,6-8,18,23-27 * * page 9, line 8-30 * * page 11, line 25-31 * * page 12-15 * ---	1-9,26	
X	EP 0 473 108 A (KANTO ISHI PHARMA CO LTD) 4 March 1992 (1992-03-04) * page 3, line 10-42 * * tables 1,2 * * claims 1,4-7 * ---	1-6,9,10,26	
X	US 5 260 280 A (ISODA HIROKO ET AL) 9 November 1993 (1993-11-09) * claims 1-11 * ---	1-7,9,10,26	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	US 5 002 759 A (GAFFAR ABDUL ET AL) 26 March 1991 (1991-03-26) * claims 1-10 * ---	1-10,26	
X	US 5 514 660 A (LANGER DENNIS H ET AL) 7 May 1996 (1996-05-07) * claims 1-3,6,7 * * example 3 * * column 5, line 31-67 * * column 6, line 1-6 * ---	1-10,26	
X	US 5 401 723 A (TYLEWSKA STANISLAWA ET AL) 28 March 1995 (1995-03-28) * claims 1-3,6,8,9,11 * * column 2, line 5-46 * * column 4, line 36-48 * ---	1-10,26	
	---		
	-/--		



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 03 00 2166

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	UKKONEN P ET AL: "Treatment of acute otitis media with an antiadhesive oligosaccharide: a randomised, double-blind, placebo-controlled trial" LANCET, XX, XX, vol. 356, no. 9239, 21 October 2000 (2000-10-21), pages 1398-1402, XP004264043 ISSN: 0140-6736 * page 1398, left-hand column, line 1-24 *	1-7,9, 10,26	
X	WO 01 43751 A (A & SCIENCE INVEST AB ;LEONARDSSON IRENE (SE); TENEBERG SUSANN (SE) 21 June 2001 (2001-06-21) * claims 4,5,10,11,24-51,56 *	1-9, 11-16,26	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	WO 99 56754 A (ABBOTT LAB) 11 November 1999 (1999-11-11) * claims 1-7,9,10 * * page 4, line 1-25 *	1-7,9, 11-16,26	
X	DE 197 01 382 A (NUTRICIA NV) 23 July 1998 (1998-07-23) * claims 1,6-8 *	1-7, 9-16,26	
X	US 6 083 934 A (PRIETO PEDRO A ET AL) 4 July 2000. (2000-07-04) * claim 1 * * examples 2,3 *	11-16	
X	EP 0 313 533 A (BIOCARB AB) 26 April 1989 (1989-04-26) * page 2, column 1, line 1-38 * * page 2, column 1, line 56-63 * * page 2, column 2, line 1-14 * * claims 1,4,7 * * example 1 *	11-16	

EPO FORM 1503 03.02 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 2166

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-05-2003

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0178748	A	25-10-2001	AU	5907701 A	30-10-2001
			WO	0178748 A2	25-10-2001
US 5164374	A	17-11-1992	WO	9211017 A2	09-07-1992
US 5177062	A	05-01-1993	JP	2235816 A	18-09-1990
			JP	2048529 A	19-02-1990
			JP	2774285 B2	09-07-1998
			AU	622989 B2	30-04-1992
			AU	5116790 A	13-09-1990
			CA	1324755 A1	30-11-1993
			DE	69000746 D1	25-02-1993
			DE	69000746 T2	27-05-1993
			DK	386657 T3	01-03-1993
			EP	0386657 A1	12-09-1990
			IL	93649 A	30-03-1995
			NZ	232782 A	26-05-1997
US 5639734	A	17-06-1997	WO	9619231 A1	27-06-1996
WO 0032205	A	08-06-2000	AU	3106300 A	19-06-2000
			CA	2353502 A1	08-06-2000
			EP	1135143 A1	26-09-2001
			US	2002142945 A1	03-10-2002
			WO	0032205 A1	08-06-2000
EP 0473108	A	04-03-1992	JP	4112829 A	14-04-1992
			AU	642523 B2	21-10-1993
			AU	8344391 A	05-03-1992
			CA	2050172 A1	01-03-1992
			EP	0473108 A2	04-03-1992
			NZ	239601 A	27-07-1997
			US	5393742 A	28-02-1995
US 5260280	A	09-11-1993	JP	2207089 A	16-08-1990
			JP	2805490 B2	30-09-1998
			DE	69006046 D1	03-03-1994
			DE	69006046 T2	04-08-1994
			EP	0385118 A2	05-09-1990
			US	5330975 A	19-07-1994
US 5002759	A	26-03-1991	US	5095106 A	10-03-1992
US 5514660	A	07-05-1996	US	5883079 A	16-03-1999
			US	5753630 A	19-05-1998
			AU	709149 B2	19-08-1999

EPO FORM P445

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 2166

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-05-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5514660 A		AU 1932395 A	18-09-1995
		CA 2183329 A1	08-09-1995
		EP 0749314 A1	27-12-1996
		JP 3179108 B2	25-06-2001
		JP 9509931 T	07-10-1997
		WO 9523605 A1	08-09-1995
		CN 1085430 A ,B	20-04-1994
		MX 9304638 A1	31-05-1994
		US 5620964 A	15-04-1997
		AU 4993893 A	03-03-1994
		WO 9403184 A1	17-02-1994
US 5401723 A	28-03-1995	NONE	
WO 0143751 A	21-06-2001	AU 2418801 A	25-06-2001
		CA 2392766 A1	21-06-2001
		CN 1411376 T	16-04-2003
		CZ 20021989 A3	16-10-2002
		EP 1237558 A1	11-09-2002
		HU 0204243 A2	28-03-2003
		NO 20022890 A	15-08-2002
		WO 0143751 A1	21-06-2001
		SK 8152002 A3	06-11-2002
WO 9956754 A	11-11-1999	US 2002019991 A1	14-02-2002
		AU 9592798 A	23-11-1999
		WO 9956754 A1	11-11-1999
		ZA 9809560 A	02-07-1999
DE 19701382 A	23-07-1998	DE 19701382 A1	23-07-1998
		AU 6210698 A	07-08-1998
		WO 9831241 A1	23-07-1998
		EP 0957692 A1	24-11-1999
US 6083934 A	04-07-2000	US 5906982 A	25-05-1999
		EP 0973413 A1	26-01-2000
		JP 2001517950 T	09-10-2001
		NO 994722 A	28-09-1999
		WO 9843495 A1	08-10-1998
EP 0313533 A	26-04-1989	SE 462134 B	14-05-1990
		AT 80523 T	15-10-1992
		DE 3874670 D1	22-10-1992
		DE 3874670 T2	22-04-1993
		EP 0313533 A1	26-04-1989
		ES 2052778 T3	16-07-1994

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

